Shots: The European Commission has granted marketing authorization for Rhokiinsa 0.02% for reducing the elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension The EC’s approval […]readmore
Tags : Ocular Hypertension
Shots: The NDA submission is based on P-III ARTEMIS studies results assessing Bimatoprost SR vs timolol in 1122 patients with open-angle glaucoma or ocular hypertension for 12wks. The P-III ARTEMIS […]readmore